Here is the design of a clinical trial:

Official Title: A Phase I/II Study of MCLA-128, a Full Length IgG1 Bispecific Antibody Targeting HER2 and HER3, in Patients With Solid Tumors (eNRGy)

Included conditions:
- Solid Tumours Harboring NRG1 Fusion
- NSCLC Harboring NRG1 Fusion
- Pancreatic Cancer Harboring NRG1 Fusion
- NRG1 Fusion

Study Armgroups:
- {'label': 'Part 2 Pancreatic adenocarcinoma harboring NRG1 fusion', 'type': 'EXPERIMENTAL', 'description': 'Participants will receive intravenous infusion of 750 mg of zenocutuzumab (MCLA-128) (the recommended Phase 2 dose (RP2D)) every 2 weeks.', 'interventionNames': ['Drug: zenocutuzumab (MCLA-128)']}
- {'label': 'Part 2 NSCLC cancer harboring NRG1 fusion', 'type': 'EXPERIMENTAL', 'description': 'Participants will receive intravenous infusion of 750 mg of zenocutuzumab (MCLA-128) (the recommended Phase 2 dose (RP2D)) every 2 weeks.', 'interventionNames': ['Drug: zenocutuzumab (MCLA-128)']}
- {'label': 'Part 2 Solid tumour (basket) harboring NRG1 fusion', 'type': 'EXPERIMENTAL', 'description': 'Participants will receive intravenous infusion of 750 mg of zenocutuzumab (MCLA-128) (the recommended Phase 2 dose (RP2D)) every 2 weeks.', 'interventionNames': ['Drug: zenocutuzumab (MCLA-128)']}

Interventions:
- {'type': 'DRUG', 'name': 'zenocutuzumab (MCLA-128)', 'description': 'full length IgG1 bispecific antibody targeting HER2 and HER3', 'armGroupLabels': ['Part 2 NSCLC cancer harboring NRG1 fusion', 'Part 2 Pancreatic adenocarcinoma harboring NRG1 fusion', 'Part 2 Solid tumour (basket) harboring NRG1 fusion'], 'otherNames': ['bispecific', 'MCLA-128']}

Primary Outcomes:
- {'measure': "Objective overall response rate (ORR) as per local investigator's assessment", 'description': 'Evaluation of clinical benefit assessed by RECIST v1.1 determining objective overall response rate (ORR)', 'timeFrame': '36 months'}
- {'measure': "Duration of response per RECIST v1.1 as per local Investigator's assessment.", 'description': 'To assess durability of anti-tumor activity of MCLA-128 in patients with NRG1 fusions as assessed locally', 'timeFrame': '36 Months'}

Please estimate the sample size based on the assumption: 
The study is designed to provide substantial evidence of effectiveness in a setting where a randomized trial will not be feasible, supporting a regulatory submission.
Sample size
          Among patients with NRG1+ NSCLC, enrollment is planned to be limited to 100 patients. Enrollment of patients with NRG1+ PDAC is planned to be limited to 50 patients, and enrollment of patients with NRG1+ in other solid tumors into aÂ basket cohort is planned to be limited to 100 patients across the various tumor types.
          The eNRGy study in patients with NRG1 fusions was designed to initially assess theÂ presence of antitumor activity in patients with NSCLC, PDAC, or other tumor types, such as breast cancer and cholangiocarcinoma. The overall sample size was increased to a maximum of 250 patients to ensure a sufficient sample size to support a regulatory submission in NSCLC (to ensure at least 100 NSCLC patients previously treated with platinum-based combination), PDAC, and/or tumor agnostic setting, where a sufficient number of patients across multiple tumor types is expected to be treated to provide substantial evidence of effectiveness in a setting where a randomized trial will not be feasible.